More action is in store in the competitive diabetes segment in India, with Glenmark Pharmaceuticals Ltd. now readying a fixed-dose combination (FDC) of the sodium glucose co-transporter-2 (SGLT2) inhibitor remogliflozin and the dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin.
The Mumbai-based company, which has shaken up the domestic diabetes segment over the recent past with the launch of separate...







